Sulfinpyrazone

Sulfinpyrazone is a phenylbutazone derivative with uricosuric and antithrombotic properties. Sulfinpyrazone competitively inhibits reabsorption of urate at the proximal renal tubule in the kidney. This agent acts on the organic anion transport exchanger, thereby increasing uric acid excretion and decreasing serum uric acid levels resulting in the prevention of urate deposition. Sulfinpyrazone also blocks tubular excretion of various acidic drugs, resulting in increased serum concentration of the drugs. Additionally, sulfinpyrazone and its active metabolite inhibit the synthesis of thromboxane A2, by competitively inhibiting the activity of cyclooxygenase, thereby preventing platelet aggregation through restoration of platelet survival time to normal, and decreasing platelet adhesiveness to subendothelial cells. It is grouped under the following drug class(es): Gout agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Diphenylpyrazone, Sulfoxyphenylpyrazolidine, Anturanil and Anturidin. Its PubChem CID is 5342.

CAS No 57-96-5
Molecular Formula C23H20N2O3S
Molecular Weight 404.5 g/mol
Synonyms 4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione

Frequently Asked Questions